96 Tests PN: B111417
45x Ab-conjugated beads (S4P12 - human IL-32 Ab-bead). PN: B111417A. One vial containing 100 µL of anti-human IL-32 conjugated to AimPlex Bead S4P12
25x Biotin-detection Ab (human IL-32 Biotin-dAb). PN: B111417B. One vial containing 100 µL of biotinylated anti-human IL-32.
Lyophilized Standard Mix-Human Group 3 Panel B, 12-Plex. PN: HG3012B. One vial containing lyophilized recombinant human IL-9, IL-15, IL-16, IL-17C, IL-23p19, IL-24, IL-27, IL-31, IL-32, IL-34, OSM, and SCF. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human IL-32. Can be multiplexed with other analytes in Human Group 3. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 10 pg/mL
LLOQ: < 20 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 3: Negligible
Sample volume: 15 µL/test
Interleukin 32 (Accession P24001) is a cytokine that is not a member of any cytokine family, as it has little homology with any well-understood cytokine. IL-32 is a pro-inflammatory cytokine that is expressed in nine different isoforms. It is produced in multiple human tissues including the thymus, lung, colon, heart, liver, kidney, brain, and pancreas. IL-32 has been identified as an important host molecule that aids in defense against tuberculosis. IL-32 is suggested as a target for future research on its ability to inhibit cancer proliferation.
Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin-32, inflammation and cancer. Pharmacol Ther. 2017; 174: 127-137. Doi: 10.1016/j.pharmthera.2017.02.025.
Li W, Deng W, Xie J. The Biology and Role of Interleukin-32 in Tuberculosis. J Immunol Res. 2018: 1545194. Doi: 10.1155/2018/1535194.
Mabilleau G, Sabokbar A. Interleukin-32 Promotes Osteoclast Differentiation but Not Osteoclast Activation. PLoS One. 2009; 4(1): e4173. Doi: 10.1371/journal.pone.0004173.
Ribeiro-Dias F, Gomes RS, de Lima Silva LL, dos Santos JC, Joosten LAB. Interleukin 32: a novel player in the control of infectious diseases. JLB. 2016. Doi: 10.1189/jib.4RU0416-175RR.